{"id":295309,"date":"2025-12-22T00:00:00","date_gmt":"2025-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0004-2024-biopharma-dry-eye-current-treatment-treatment-algorithms-claims-data-analysis-dry\/"},"modified":"2026-04-17T11:14:59","modified_gmt":"2026-04-17T11:14:59","slug":"algoop0004-2025-biopharma-dry-eye-current-treatment-treatment-algorithms-claims-data-analysis-dry-eye-disease-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0004-2025-biopharma-dry-eye-current-treatment-treatment-algorithms-claims-data-analysis-dry-eye-disease-us\/","title":{"rendered":"Dry Eye &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Dry Eye Disease (US)"},"content":{"rendered":"<p>The dry eye disease (<abbr title=\"dry eye disease\">DED<\/abbr>) market is evolving rapidly, driven by innovative treatments and a growing understanding of the condition. Historically dominated by AbbVie\u2019s Restasis, the market has seen a surge of new <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved therapies in the last five years. These agents include Alcon\u2019s Eysuvis and Viatris \/ Oyster Point\u2019s Tyrvaya with its unique intranasal delivery system. The latest entrants, Bausch + Lomb \/ Novaliq\u2019s Miebo, the first and only therapy specifically approved for treating evaporative <abbr title=\"dry eye disease\">DED<\/abbr>, and Harrow \/ Novaliq\u2019s Vevye, further expand physicians\u2019 treatment armamentarium as the only water-free, cyclosporine-based agents approved for treating both signs and symptoms of <abbr title=\"dry eye disease\">DED<\/abbr>. Beyond conservative measures like lid hygiene and artificial tears, the management of <abbr title=\"dry eye disease\">DED<\/abbr> also includes the prescription of off-label ophthalmic corticosteroids and antibiotics.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"dry eye disease\">DED<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"dry eye disease\">DED<\/abbr> patients?<\/li>\n<li>How has Vevye been integrated into the treatment algorithm, and what is its source of business?<\/li>\n<li>What percentage of <abbr title=\"dry eye disease\">DED<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"dry eye disease\">DED<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Bausch + Lomb, Sun Ophthalmics, Kala Pharmaceuticals, Alcon, Viatris, Novaliq, Harrow<\/p>\n<p><strong>Key drugs:<\/strong> Restasis, Restasis MultiDose, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><b>Product enhancement<\/b><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-295309","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-dry-eye","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295309\/revisions"}],"predecessor-version":[{"id":571910,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295309\/revisions\/571910"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}